Thrombosis - Besieged but Poorly Understood.

Authors:
Lang IM.

Journal:
Front Cardiovasc Med

Publication Year: 2014

DOI:
10.3389/fcvm.2014.00004

PMCID:
PMC4668866

PMID:
26664856

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Front Cardiovasc Med

Abbreviation: Front Cardiovasc Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Cardiac & Cardiovascular Systems

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A Bayesian network-based approach for identifying risk factors and predicting ischemic stroke in in…
Yuan B; Wang C; Fan Z and 6 more (2024) - Transparency Score: 3/6
A contemporary update on cancer and takotsubo syndrome.
Tini G; Arcari L; Mistrulli R and 9 more (2024) - Transparency Score: 3/6
A cross-sectional analysis of zinc and copper levels and their relationship to cardiovascular disea…
Kerkadi A; Raïq H; Prince MS and 3 more (2024) - Transparency Score: 3/6
Advancements in cardiac structures segmentation: a comprehensive systematic review of deep learning…
Alnasser TN; Abdulaal L; Maiter A and 6 more (2024) - Transparency Score: 4/6
A nomogram for predicting left atrial thrombus or spontaneous echo contrast in non-valvular atrial …
Zeng D; Zhang X; Chang S and 4 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of Interest Statement Irene M. Lang has relationships with drug companies including AOPOrphan Pharmaceuticals, Abbott, Actelion, Astra-Zeneca, Bayer-Schering, Cordis, Glaxo Smith Kline, Medtronic, Novartis, Pfizer, Servier, and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service, research grants, and membership of scientific advisory boards."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025